PACIFICHEALTH LABORATORIES INC
SC 13D, 2000-02-11
DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES
Previous: GABRIEL CAPITAL CORP, 13F-HR, 2000-02-11
Next: AMERIPRIME FUNDS, 485APOS, 2000-02-11





                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                  SCHEDULE 13D

                    UNDER THE SECURITIES EXCHANGE ACT OF 1934


                        PacificHealth Laboratories, Inc.
                        --------------------------------
                                (Name of Issuer)


                         Common Stock, $.0025 par value
                         ------------------------------
                         (Title of Class of Securities)


                                   695113 10 0
                                 --------------
                                 (CUSIP Number)


                   Jonathan D. Rahn. Executive Vice President
                          1480 Route 9 North, Suite 204
                              Woodbridge, NJ 07095
                                  732/636-6141
                -------------------------------------------------
                  (Name, Address and Telephone Number of Person
                Authorized to Receive Notices and Communications)


                                   Copies to:
                             Joseph Chicco, Esquire
                      Eckert Seamans Cherin & Mellott, LLC
                         1515 Market Street - 9th Floor
                                Philadelphia, PA
                                  215/851-8410


                                  March 9, 1999
             -------------------------------------------------------
             (Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box |_|

NOTE: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.

*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).


<PAGE>


                                 SCHEDULE 13D

- -------------------------------------------------------------------------------
1     |      NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSONS
      |
      |      Robert Portman
- -------------------------------------------------------------------------------
2     |      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
      |      (See Instructions)                                       (a) |_|
      |                                                               (b) |_|
- --------------------------------------------------------------------------------
3     |      SEC USE ONLY
      |
      |
- --------------------------------------------------------------------------------
4     |      SOURCE OF FUNDS (see Instructions)
      |
      |      PF
- --------------------------------------------------------------------------------
5     |      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
      |      TO ITEMS 3(d) OR 2(e)
      |      Not Applicable
- --------------------------------------------------------------------------------
6     |      CITIZENSHIP OR PLACE OF ORGANIZATION
      |
      |      USA (New Jersey)
- --------------------------------------------------------------------------------
                                   |  7  |   SOLE VOTING POWER
                                   |     |
                                   |     |   744,767 shares
      NUMBER OF SHARES             |-----|--------------------------------------
        BENEFICIALLY               |  8  |   SHARED VOTING POWER
       OWNED BY EACH               |     |
      REPORTING PERSON             |     |   -0-
            WITH                   |-----|--------------------------------------
                                   |  9  |   SOLE DISPOSITIVE POWER
                                   |     |
                                   |     |   744,767 shares
                                   |-----|--------------------------------------
                                   |  10 |   SHARED DISPOSITIVE POWER
                                   |     |
                                   |     |   -0-
- --------------------------------------------------------------------------------
11  |   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    |   1,586,434 shares of Common Stock including 841,667 shares issuable
    |   upon the exercise of presently exercisable options
- --------------------------------------------------------------------------------
12  |   CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
    |   SHARES (See Instructions)
    |                                                                    |X|
- --------------------------------------------------------------------------------
13  |   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    |
    |     29.4%
- --------------------------------------------------------------------------------
14  |    TYPE OF REPORTING PERSON (see Instructions)
    |
    |    IN
- --------------------------------------------------------------------------------


<PAGE>


ITEM 1. SECURITY AND ISSUER.

     This statement on Schedule 13D (this "Statement") relates to the common
stock, $.0025 par value (the "Common Stock") of PacificHealth Laboratories,
Inc., 1460 Route 9 North, Woodbridge, NJ 07095.

ITEM 2. IDENTITY AND BACKGROUND.

        (a) - (b)  Robert Portman
                   188 Igoe Road
                   Morganville, NJ  07751

        (c)        President and Chief Executive Officer
                   PacificHealth Laboratories, Inc.
                   1480 Route 9 North, Suite 204
                   Woodbridge, NJ 07095

        (d)        None

        (e)        None

        (f)        USA (New Jersey)

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

        Personal funds ($22,800) were used for the acquisitions described in
        Item 5(c) below.

ITEM 4. PURPOSE OF TRANSACTION.

        Personal investment.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

        Robert Portman's interests in securities of the issuer as of the date of
        this Statement are as follows:

        (a)(i)     Common Stock:

                   744,767 shares owned directly

                   200,000 shares owned by Robert Portman's spouse, as to which
                   beneficial ownership is disclaimed

           (ii)    Options to buy Common Stock:

                   Presently exercisable options to purchase 841,667 shares, as
                   follows:

                                                                     Expiration
                   # of Shares               Exercise Price             Date
                   -----------               --------------          ----------
                    300,000                      $2.00                4/30/2000
                    225,000                       3.75                3/31/2000
                    316,667                       6.00                1/1/2003
                    -------
                    841,667

                   Additional options to purchase Common Stock which are not
                   presently exercisable, as follows:

                   No. of          Date First         Exercise       Expiration
                   Shares         Exercisable          Price            Date
                   -------        -----------         --------       ----------
                   200,000          3/2/2000            $2.25          3/2/2004
                   100,000         11/4/2000             1.75         11/4/2004
                   158,333          1/1/2001             6.00          1/1/2003
                   -------
                   458,333

        (b)        Robert Portman has the sole power to vote and dispose of
                   744,767 shares owned directly, and will have sole power to
                   vote and dispose of all shares issuable upon the exercise of
                   options.

                   Robert Portman's spouse has the sole power to vote and
                   dispose of 200,000 shares owned by Mrs. Portman.

        (c)        Recent transactions by Robert Portman are as follows:

                   3/2/99 - open market purchase of 5,000 shares at
                            $2.00 per share
                   4/1/99 - open market purchase of 10,000 shares at
                            $1.28 per share


<PAGE>


ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO
        SECURITIES OF THE ISSUER.

        None.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.

        None.


                                    SIGNATURE

     After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.


                                            PacificHealth Laboratories, Inc.

                                            /s/ Robert Portman
                                            --------------------------------
                                            ROBERT PORTMAN

                                            Title President
                                                  --------------------------

                                            Dated February 10, 2000
                                                  --------------------------




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission